Discussion
The U.S. Food and Drug Administration (FDA) has granted fast track designation to EG-501, an experimental oral therapy being developed by Evergreen Therapeutics to treat cognitive impairment associated with neuropsychiatric systemic lupus erythematosus (NPSLE-CI), a form of lupus that’s marked by neurological problems. The FDA’s fast track…